NO993738L - 2-amino-substituerte pyridiner som kan anvendes ved behandling ved arteriosclerose og hyper-lipoproteinemi - Google Patents

2-amino-substituerte pyridiner som kan anvendes ved behandling ved arteriosclerose og hyper-lipoproteinemi

Info

Publication number
NO993738L
NO993738L NO993738A NO993738A NO993738L NO 993738 L NO993738 L NO 993738L NO 993738 A NO993738 A NO 993738A NO 993738 A NO993738 A NO 993738A NO 993738 L NO993738 L NO 993738L
Authority
NO
Norway
Prior art keywords
amino
substituted pyridines
arteriosclerosis
treatment
lipoproteinemia
Prior art date
Application number
NO993738A
Other languages
English (en)
Other versions
NO993738D0 (no
Inventor
Carsten Schmeck
Arndt Brandes
Michael Loegers
Gunter Schmidt
Klaus-Dieter Bremm
Hilmar Bischoff
Delf Schmidt
Joachim Schuhmacher
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO993738D0 publication Critical patent/NO993738D0/no
Publication of NO993738L publication Critical patent/NO993738L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det beskrives nye 2-amino-substituerte pyridiner med formel (I). Disse fremstilles ved først å omdanne tilsvarende pyridinaldehyder til tilsvarende hydroksyder ved hjelp av metallorganiske forbindelser som Grignard-forbindelser og så å redusere hydroksydene til en deshydroksyforbindelse. De nye 2-amino-substituerte pyridiner er egnet for anvendelse som aktive bestanddeler i medikamenter og særlig slike som benyttes ved behandling av arteriosklerose.
NO993738A 1997-02-05 1999-08-02 2-amino-substituerte pyridiner som kan anvendes ved behandling ved arteriosclerose og hyper-lipoproteinemi NO993738L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19704243A DE19704243A1 (de) 1997-02-05 1997-02-05 Neue 2-Amino-substituierte Pyridine
PCT/EP1998/000362 WO1998034920A1 (de) 1997-02-05 1998-01-23 2-amino-substituierte pyridine verwendbar zur behandlung von arteriosklerose und hyperlipoproteinemie

Publications (2)

Publication Number Publication Date
NO993738D0 NO993738D0 (no) 1999-08-02
NO993738L true NO993738L (no) 1999-09-17

Family

ID=7819326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993738A NO993738L (no) 1997-02-05 1999-08-02 2-amino-substituerte pyridiner som kan anvendes ved behandling ved arteriosclerose og hyper-lipoproteinemi

Country Status (19)

Country Link
EP (1) EP0973744A1 (no)
JP (1) JP2001510478A (no)
KR (1) KR20000070756A (no)
CN (1) CN1252057A (no)
AU (1) AU730109B2 (no)
BG (1) BG103631A (no)
BR (1) BR9807181A (no)
CA (1) CA2279636A1 (no)
CZ (1) CZ279299A3 (no)
DE (1) DE19704243A1 (no)
HU (1) HUP0001022A2 (no)
ID (1) ID24208A (no)
IL (1) IL131127A0 (no)
NO (1) NO993738L (no)
NZ (1) NZ337011A (no)
PL (1) PL334899A1 (no)
SK (1) SK104099A3 (no)
TR (1) TR199901857T2 (no)
WO (1) WO1998034920A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP4547148B2 (ja) 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
RU2330682C2 (ru) 2003-09-26 2008-08-10 Джапан Тобакко Инк. Способ ингибирования продуцирования остаточных липопротеинов
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006032987A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
EP2548894A1 (en) 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis

Also Published As

Publication number Publication date
TR199901857T2 (xx) 1999-10-21
JP2001510478A (ja) 2001-07-31
KR20000070756A (ko) 2000-11-25
NO993738D0 (no) 1999-08-02
ID24208A (id) 2000-07-13
AU730109B2 (en) 2001-02-22
NZ337011A (en) 2001-04-27
AU6212398A (en) 1998-08-26
CN1252057A (zh) 2000-05-03
EP0973744A1 (de) 2000-01-26
WO1998034920A1 (de) 1998-08-13
CA2279636A1 (en) 1998-08-13
DE19704243A1 (de) 1998-08-06
PL334899A1 (en) 2000-03-27
HUP0001022A2 (hu) 2000-09-28
SK104099A3 (en) 2000-01-18
BR9807181A (pt) 2000-01-25
CZ279299A3 (cs) 1999-11-17
IL131127A0 (en) 2001-01-28
BG103631A (en) 2000-11-30

Similar Documents

Publication Publication Date Title
GEP20012578B (en) (54) Heteroaryl Succinamides, Pharmaceutical Compositions Containing the Same and Methods for Treatment of the Diseases Caused by Metalloproteinase Activity
GEP20032922B (en) Benzoheterocycles and Their Use as MEK Inhibitors
NO20074773L (no) Caspaseinhibitorer og anvendelse derav
NO983003L (no) Vitronectin-reseptor-antagonister
DE69919334D1 (de) Phenylalaninderivate als inhibitoren von alpha4 integrinen
ATE191218T1 (de) Rapamycin-derivate als immunosuppressoren
NO20030301L (no) Nye heteroarylderivater og anvendelse derav som farmasöytika
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
ATE260910T1 (de) 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester- transfer-proteins (ctep)
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
WO1998042659A3 (en) Aryl- or heteroarylsulfonamide substituted hydroxamic acid derivates, process for their preparation and their use as pharmaceuticals
CA2015838A1 (en) Method of topically treating acne vulgaris
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP1695711A3 (en) Parenteral formulations comprising boronic acid species for selective thrombin inhibition
GEP20002187B (en) Carboxamide Derivatives of Pyrrolidine, Piperidine and Hexahydroazepine, Composition for the Treatment of Thrombosis Disorders Induced by Thrombocytes, Intermediate Compounds and Method for Their Preparation
ATE267187T1 (de) Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen
ATE233252T1 (de) Substituierte dihydrobenzofurane als pde- hemmstoffe
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
ATE365535T1 (de) Verfahren zur behandlung der haut durch elektrostatisches versprühen einer emulsion enthaltend eine isolierende äussere und eine leitende innere phase
TR199901857T2 (xx) Yeni 2-amino-ikameli piridinler
DK1083887T3 (da) Farmaceutisk præparat til behandling af ulcera
NO970123L (no) Ny kjemisk forbindelse, dens fremstilling og anvendelse som legemiddel
DE69736945D1 (de) Biphenylverbindungen sowie ihre anwendung als östrogene mittel
ATE115949T1 (de) Substituierte mandelsäurederivate, als 5- lipoxygenasehemmer.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application